BrainChild Bio raises $119M Series A to fund pivotal Phase 2 of CAR T BCB-276 for deadly pediatric DIPG
BrainChild Bio raised $119 million in a Series A to advance CAR T therapies for pediatric central nervous system cancers, funding a pivotal Phase 2 trial of lead asset BCB-276 for diffuse intrinsic pontine glioma (DIPG) and preclinical work on BCB-214.
More: FinSMEs, Endpoints News, Fierce Biotech, GEN - Genetic Engineering and Biotechnology News, American Chemical Society
- FinSMEs: BrainChild Bio Raises $116M Series A to Fund Phase 2 ILLUMINATE Trial of BCB‑276 for DIPG
-
Endpoints News / Kyle LaHucik: BrainChild Bio raises $116M Series A to fund pivotal B7-H3 CAR-T trial for pediatric DIPG
- Also at: Fierce Biotech, GEN - Genetic Engineering and Biotechnology News, American Chemical Society
No comments yet.